CAB39 Antibody (N-term) Blocking Peptide

CAB39 Antibody (N-term) Blocking Peptide

€363.00
In stock
SKU
AC-BP1650a
Catalog Number: AC-BP1650a
Size: 500 µg
Datasheet
Request Information
Background:
CAB39 together with the STE20-related adaptor-alpha (STRAD alpha) pseudo kinase, forms a regulatory complex capable of stimulating the activity of the LKB1 tumor suppressor protein kinase. The latter is mutated in the inherited Peutz-Jeghers cancer syndrome (PJS). CAB39 binds directly to a conserved Trp-Glu-Phe sequence at the STRAD alpha C terminus, markedly enhancing binding of STRAD alpha to LKB1 and increasing LKB1 catalytic activity. Skeletal muscle contraction results in the phosphorylation and activation of the AMP-activated protein kinase (AMPK) by an upstream kinase (AMPKK). The LKB1-STE-related adaptor (STRAD)-CAB39 complex is the major AMPKK in skeletal muscle; however, LKB1-STRAD-CAB39 activity is not increased by muscle contraction. This relationship suggests that phosphorylation of AMPK by LKB1-STRAD-CAB39 during skeletal muscle contraction may be regulated by allosteric mechanisms.

Other Names:
Calcium-binding protein 39, MO25alpha, Protein Mo25, CAB39, MO25

Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP1650a was selected from the N-term region of human CAB39. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Gene Name: CAB39

Gene ID: 51719
Primary Accession: Q9Y376
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
More Information
Is Featured? No
Write Your Own Review
You're reviewing:CAB39 Antibody (N-term) Blocking Peptide